Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Capital Expenditures (2020 - 2024)

Celularity has reported Capital Expenditures over the past 5 years, most recently at $31000.0 for Q4 2024.

  • Quarterly results put Capital Expenditures at $31000.0 for Q4 2024, down 94.66% from a year ago — trailing twelve months through Dec 2024 was $87000.0 (down 91.7% YoY), and the annual figure for FY2024 was $87000.0, down 91.7%.
  • Capital Expenditures for Q4 2024 was $31000.0 at Celularity, down from $35000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for CELU hit a ceiling of $9.4 million in Q4 2020 and a floor of -$1.9 million in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $580000.0 (2023), compared with a mean of $1.3 million.
  • Peak annual rise in Capital Expenditures hit 217.36% in 2022, while the deepest fall reached 239.36% in 2022.
  • Celularity's Capital Expenditures stood at $9.4 million in 2020, then plummeted by 50.9% to $4.6 million in 2021, then decreased by 8.26% to $4.2 million in 2022, then tumbled by 86.26% to $580000.0 in 2023, then tumbled by 94.66% to $31000.0 in 2024.
  • The last three reported values for Capital Expenditures were $31000.0 (Q4 2024), $35000.0 (Q3 2024), and -$18000.0 (Q2 2024) per Business Quant data.